(UroToday.com) The ANZUP annual scientific meeting’s clinical trials session included an update in germ cell tumors provided by Dr. Ben Tran. Specifically, this included an update on 5 ongoing trials/projects that ANZUP is involved with. The first trial discussed by Dr. Tran was the P3BEP trial, a randomized phase 3 trial of accelerated versus standard BEP chemotherapy for intermediate and poor risk metastatic germ cell tumors. Male and female participants 11-45 years of age with intermediate or poor-risk metastatic germ cell tumor are randomized to Arm A (standard BEP 4 x 21 day cycles) versus Arm B (accelerated BEP 4 x 14 day cycles). End of chemotherapy treatment and safety assessment is performed at 30-42 days after the last study dose, followed by surgical resection of any residual disease +/- further chemotherapy. The final response assessment occurs at 6 months from randomization or after all post-chemotherapy surgery and other interventions are complete. The trial schema for P3BEP is as follows: